PUNE, India, December 7, 2015 /PRNewswire/ --
ReportsnReports.com adds "Emphysema - Pipeline Review, H2 2015" market research report that aims to help enhance decision making capabilities and create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this emphysema pipeline report include Angion Biomedica Corp., Intrexon Corporation, ProMetic Life Sciences Inc. and rEVO Biologics, Inc. Drug profiles discussed in this report include Alpha-1 Antitrypsin With rHuPH20, alpha-1 proteinase inhibitor (human), BB-3, EDO-66, MG-53, Monoclonal Antibody to Inhibit EMAP II for Emphysema, Recombinant Human Alpha-1 Antitrypsin and TRN-101. Complete report on H2 2015 pipeline review of Emphysema with 4 companies and 8 drug profiles, spread across 41 pages is available at http://www.reportsnreports.com/reports/445723-emphysema-pipeline-review-h2-2015.html .
This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects.
List of Tables
Number of Products under Development for Emphysema, H2 2015
Number of Products under Development for Emphysema - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Emphysema Therapeutics - Recent Pipeline Updates, H2 2015
Emphysema - Dormant Projects, H2 2015
Order a copy of this report at http://www.reportsnreports.com/purchase.aspx?name=445723 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Emphysema and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Emphysema and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects and review of the Emphysema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Emphysema pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.
Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+ 1 888 391 5441
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts